Henlix Biotech Inc., an innovative biopharmaceutical company, was co-founded by two American biopharmaceutical veterans, Dr. Scott Liu and Dr. Weidong Jiang in October 2010, in Taiwan and expanded its research site in the San Francisco Bay Area. The company specializes in the discovery and development of innovative monoclonal antibody therapeutics, bi-specific antibodies and antibody drug conjugates (ADCs) by using state of the art technologies. With its core mission in making quality antibody-based therapeutics available and affordable to all patients in need worldwide, Henlix aims to become a trusted leading international biopharmaceutical company with a significant global impact.
Efficient R&D Independent innovation People-oriented
To date, Henlix has 6 innovative antibody-based therapeutics candidates in the pipeline; the lead product has entered a Phase I clinical trial in 2016. The company targets to file at least 1 IND per year. Henlix has established a state of the art antibody discovery and development engine to accelerate multiple promising novel antibody candidates to the clinic in a cost-effective manner. Henlix emphasizes on teamwork, cares for the growth and development of each employee, endeavors to construct a fair and just, as well as positive working environment, so as to create a productive work environment for the employees' career growth.
Henlix Biotech Co., Ltd. has been awarded the 13th National Innovation Award for Development and Application of an Innovative Monoclonal Antibody HLX07 for Cancer Therapy in the Pharmaceutical and New Medical Technology Category by the Institute for Biotechnology and Medicine Industry.
HLX07 Investigational New Drug Application (IND) was approved by Taiwan, US and Chinese Food and Drug Administration, Phase I trial was started in August 2016.
In January 2016, Henlix completed financing of 258,000,000 NT dollars, with the actual receipt capital of 663,000,000 NT dollars.
In June 2015, Henlix's authorized capital was 100,000,000 NT dollars, with actual receipt capital of 404,000,000 NT dollars.
In November 2014, Henlix completed financing of 240,000,000 NT dollars, under 96.4% of holdings, by U.S. Henlix.
In July 2014, Henlix positioned its research and development focus on innovative monoclonal antibody development.
In April 2014, Henlix Biotech Inc. was restructured into Henlix Biotech Ltd.
In March 2013, Henlix completed financing of 8,780,000 NT dollars, with actual receipt capital of 8,880,000 NT dollars.
In 2012, Henlix started to provide R&D service of innovative monoclonal antibody for U.S Henlix and Shanghai Henlius
In 2011, Henlix cooperated with the Industry-Academy Cooperation Incubation Center of the Taipei Medical College to conduct the research project of innovative monoclonal antibodies.
In October 2010, the Henlix Biotech Inc.was founded in Taiwan.